The Renji Hospital Biobank, also known as the Renji Biobank, was established in 2008 and officially founded in 2013 with funding from the hospital, the special project of the Shanghai Science and Technology Commission, the "985" construction project of Shanghai Jiao Tong University School of Medicine, and the Professional Technical Service platform Project of Shanghai. It was meticulously planned and constructed in accordance with international biobanking guidelines and standards. With a mission to advance life and health research and to support basic and clinical investigations, the biobank has pioneered the "Renji model," which prioritizes patient-centricity, clinical relevance, and scientific rigor. Over the years, it has contributed to more than 80 projects, spanning from single-disease characteristic resource projects to multi-center clinical studies and large population cohort initiatives. In 2020, the biobank underwent expansion and relocation to the New Research Building, boasting a spacious area of 1500 square meters and a capacity to accommodate 6 to 8 million vials. Operating under the oversight of the hospital's Ethics Committee and Scientific Committee, the Renji Biobank has established standardized platforms for sample pre-processing, quality control, storage, and integrated information management. As of February 2024, it has amassed nearly 100,000 donors and 1.5 million samples, covering a diverse array of sample types including whole blood, serum, plasma, urine, tissues, and more. Moreover, the biobank offers a suite of high-throughput technical services such as nucleic acid and protein extraction, tissue chip preparation, and tumor organoid culture. Its disease spectrum encompasses over 50 categories, including tumors, autoimmune diseases, cardiovascular ailments, and metabolic disorders, thus enabling support for large-scale cohort studies, personalized medicine endeavors, multi-omics research, biomarker discovery, and validation efforts. Renji Biobank holds prestigious affiliations as the "Shanghai Major Disease Biobanking Professional Technical Service Platform," the branch of the "Shanghai Jiaotong University School of Medicine Biobank," and an initiating unit of the "China Biobank Alliance." Additionally, it actively contributes to national biobanking standards, having participated in the drafting and publication of 11 such standards. In recognition of its commitment to quality and compliance, the biobank obtained the National Human Genetic Resources Preservation Administrative License from the Ministry of Science and Technology in 2016 and 2021, and in February 2024, it was awarded the biobanking accreditation certificate (registration number: BB0017) by the China National Accreditation Service for Conformity Assessment (CNAS).

Our vision is to integrate biospecimen science into medical research and foster resource sharing to advance the field of medicine. As a pivotal player in the "Shanghai Major Disease Biobank-Professional Technical Service Platform," the "Shanghai Jiaotong University School of Medicine Biobank-Branch," and the initiating unit of the "China Biobank Alliance," we are committed to fostering disease-specific alliances, collaborative research endeavors, and industrial transformations, thereby facilitating sample-driven advancements across various professional domains and ultimately enhancing public health outcomes.

Address: 1-2 Floor, Research Building, Renji Hospital, Biological Resource Center, Renji Hospital, Shanghai Jiaotong University School of Medicine, 1630 Dongfang Road, Pudong New Area, Shanghai

Zip code: 200127

Service tel: 021-68382652

Technical consultation: 021-68382652

Public mailbox: RJ_biobank@163.com